Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157933 | 0.89 | SIRT2 (0.35) | TDP1SIRT2RORCMEN1KMT2A | |
| SCHEMBL4913480 | 0.81 | TLR7 (0.44) | TDP1RORCALDH1A1GPBAR1TLR7 | |
| SCHEMBL4150093 | 0.81 | KMT2A (0.39) | EPAS1TDP1SIRT2MEN1KMT2A | |
| SCHEMBL4153993 | 0.78 | RORC (0.37) | TDP1SIRT2RORCGPBAR1TLR7 | |
| SCHEMBL13774593 | 0.78 | RORC (0.39) | TDP1SIRT2RORCTLR7POLB | |
| SCHEMBL4154435 | 0.78 | RORC (0.36) | TDP1SIRT2RORCGPBAR1TLR7 | |
| SCHEMBL13774589 | 0.77 | RORC (0.39) | TDP1SIRT2RORCALDH1A1GPBAR1 | |
| SCHEMBL4158854 | 0.76 | RORC (0.35) | TDP1SIRT2RORCGPBAR1TLR7 | |
| SCHEMBL4145216 | 0.76 | RORC (0.38) | TDP1SIRT2RORCALDH1A1POLB | |
| SCHEMBL4915675 | 0.75 | TLR7 (0.38) | TDP1RORCMEN1KMT2ATLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1937629-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007046513-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | BTK, BRIX1, NFXL1 | EPAS1 4546/4885TDP1 1690/4885SIRT2 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.